
Patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) therapy are at higher risk for poor COVID‐19 outcomes and show substantially impaired humoral anti‐SARS‐CoV‐2 vaccine responses. However, the complex relationship between antigen‐specific B and T cells and the level of B cell repopulation necessary to achieve anti‐vaccine responses remain largely unknown. Antibody responses to SARS‐CoV‐2 vaccines and induction of antigen‐specific B and CD4/CD8 T cell subsets were studied in 19 rheumatoid arthritis (RA) and ANCA‐associated vasculitis (AAV) patients receiving RTX, 12 RA patients on other therapies and 30 healthy controls after SARS‐CoV‐2 vaccination with either mRNA or vector based vaccines...
Like
Save
Share